We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

The treatment is recommended for people aged 12 to 65 who have moderate to severe and persistent allergic rhinitis and have been diagnosed through clinical history and a positive test of their house ...

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

All NICE products on people with learning disabilities. Includes any guidance and quality standards.

All NICE products on physical activity. Includes any guidance and quality standards.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.